Post-Market BTVA Registry

The BTVA Registry will enroll up to 300 patients with upper lobe predominant emphysema that are being treated with BTVA at sites located in the EU and other select geographies. Patients will be followed as per standard of care and the registry will collect follow-up data for five years following treatment. The follow up data collected will include pulmonary function measurements (spirometry, body plethysmography, and diffusing capacity for carbon monoxide), exercise capacity (six minute walk test), imaging findings (chest x-ray and CT), and a quality of life questionnaire (SGRQ-C). All serious and non-serious adverse events will also be collected for the duration of the study in order to assess safety. Serious adverse events will be adjudicated by an independent medical monitor in order to establish relatedness to the InterVapor device and procedure.

Descriptive statistics will be used to summarize all safety and effectiveness data. There is no predefined hypothesis regarding the magnitude of effectiveness of InterVapor or the incidence of specific safety outcomes.

Monitoring of the registry study will be undertaken as a continuous process to ensure that high-quality data are obtained and to ensure compliance with registry procedures.

Inclusion criteria

• Patients will have heterogeneous emphysema, as evidenced by high-resolution computed tomography (HRCT) demonstrating a heterogeneity index > or equal to 1.2 in at least one segment to be treated
• Patients must be > or equal to 18 years of age
• Patients are required to provide informed consent prior to inclusion in the Registry

Exclusion criteria

• FEV1 < 20% predicted
• DLCO < 20% predicted
• Inability to walk > 140 meters in 6 minutes (6MWD) following optimized medical management
• Unstable COPD (any of the following):

• > 3 COPD related hospitalizations requiring antibiotics in past 12 months
• COPD related hospitalization in past 3 months
• daily use of systemic steroids, i.e. > 5 mg prednisolone
• Concomitant illnesses or medications that would pose a significant increased risk for complications following treatment with InterVapor. Examples of particular relevance include: immune system disorders, immunosuppressant medications of clinical relevance, bleeding disorders and unstable cardiovascular conditions, history of asthma or alpha-1 antitrypsin deficiency
• Newly prescribed morphine derivatives within the last 4 weeks
• Pregnant or breastfeeding
• Highly diseased lower lobes (tissue to air ratio of <11%)
• Bacterial infection or symptoms indicative of active infection (i.e., fever, elevated white blood cell count)
• Presence of single large bulla (defined as > 1/3 volume of lobe) or a paraseptal distribution of emphysema in the treated lobe
• Recent respiratory infections or COPD exacerbation in preceding 6 weeks -